filings.toolsItem 5. MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
4K characters. Original on sec.gov ·
Item 5. MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
The principal market for our common stock is the NYSE. Our common stock currently trades on the NYSE under the symbol “PFE”. As of February 23, 2021, there were 139,582 holders of record of our common stock.
The following summarizes purchases of our common stock during the fourth quarter of 2020(a):
| Period | Total Number of Shares Purchased(b) | Average Price Paid per Share(b) | Total Number of Shares Purchased as Part of Publicly Announced Plan | Approximate Value of Shares that May Yet Be Purchased Under the Plan(a) | |||||||||||||||||||
| September 28 through October 25, 2020 | 26,921 | $ | 36.99 | — | $ | 5,292,881,709 | |||||||||||||||||
| October 26 through November 30, 2020 | 84,279 | $ | 37.48 | — | $ | 5,292,881,709 | |||||||||||||||||
| December 1 through December 31, 2020 | 69,317 | $ | 37.39 | — | $ | 5,292,881,709 | |||||||||||||||||
| Total | 180,517 | $ | 37.37 | — |
| Pfizer Inc. | 2020 Form 10-K | 21 |
(a)See Note 12.
(b)Represents (i) 174,555 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 5,962 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.
PEER GROUP PERFORMANCE GRAPH
The following graph assumes a $100 investment on December 31, 2015, and reinvestment of all dividends, in each of the Company’s Common Stock, the S&P 500 Index, and a composite peer group of the major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Roche and Sanofi.
Five Year Performance
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |||||||||||||||||||||||||||||||||
| PFIZER | $100.0 | $104.5 | $120.9 | $151.0 | $140.5 | $145.4 | ||||||||||||||||||||||||||||||||
| PEER GROUP | $100.0 | $100.8 | $118.1 | $127.8 | $155.3 | $161.7 | ||||||||||||||||||||||||||||||||
| S&P 500 | $100.0 | $112.0 | $136.4 | $130.4 | $171.4 | $203.0 |
| Pfizer Inc. | 2020 Form 10-K | 22 |
Previous: Item 3. LEGAL PROCEEDINGS · Next: Item 6. SELECTED FINANCIAL DATA